Jun Kuroda - Taisho Pharmaceutical Ex Director
| TAIPYDelisted Stock | USD 14.00 0.00 0.00% |
Insider
Jun Kuroda is Ex Director of Taisho Pharmaceutical Holdings
| Age | 65 |
| Phone | 81 3 3985 2020 |
| Web | https://www.taisho-holdings.co.jp |
Taisho Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0183 % which means that it generated a profit of $0.0183 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0345 %, meaning that it generated $0.0345 on every $100 dollars invested by stockholders. Taisho Pharmaceutical's management efficiency ratios could be used to measure how well Taisho Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Roman | Viatris | 54 | |
| Sanjeev Narula | Viatris | 63 | |
| Deepak MBA | Dr Reddys Laboratories | 49 | |
| CA BEc | HUTCHMED DRC | 57 | |
| Joyce Lee | Elanco Animal Health | 47 | |
| Galia Inbar | Teva Pharma Industries | N/A | |
| Penny Wan | Dr Reddys Laboratories | N/A | |
| Roy MD | Pacira BioSciences, | 62 | |
| Kay Schmidt | Catalent | 61 | |
| Abbas Hussain | Teva Pharma Industries | 55 | |
| Weiguo BSc | HUTCHMED DRC | 66 | |
| Tal Zaks | Teva Pharma Industries | 55 | |
| Karen Santiago | Catalent | 53 | |
| Tamara Rogers | Haleon plc | 54 | |
| Paul Herendeen | Elanco Animal Health | 65 | |
| Ricci Whitlow | Catalent | 51 | |
| Julien Meissonnier | Catalent | N/A | |
| Robert Sr | Emergent Biosolutions | 67 | |
| Michael Grippo | Catalent | 55 | |
| R Hoover | Elanco Animal Health | 75 | |
| Erez MBA | Dr Reddys Laboratories | 56 | |
Management Performance
| Return On Equity | 0.0345 | |||
| Return On Asset | 0.0183 |
Taisho Pharmaceutical Leadership Team
Elected by the shareholders, the Taisho Pharmaceutical's board of directors comprises two types of representatives: Taisho Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taisho. The board's role is to monitor Taisho Pharmaceutical's management team and ensure that shareholders' interests are well served. Taisho Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taisho Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shigeru Uehara, Vice President and Presidentident of Subsidiary, Director | ||
| Shinichi Tanaka, Gen Communications | ||
| Akira Uehara, President Chairman of Subsidiary, Representative Director | ||
| Jinsei Maruyama, Co Officer | ||
| Tetsu Watanabe, Executive Director | ||
| Jun Kuroda, Ex Director | ||
| Ken Uehara, MD Director | ||
| Hideki Iuchi, G Mang | ||
| Hisashi Umeoka, Director |
Taisho Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Taisho Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0345 | |||
| Return On Asset | 0.0183 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.27 B | |||
| Shares Outstanding | 327.94 M | |||
| Price To Earning | 20.67 X | |||
| Price To Book | 0.57 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 268.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Taisho Pink Sheet
If you are still planning to invest in Taisho Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taisho Pharmaceutical's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |